BactiQuant (BACTIQ) Q2 2025 TU earnings summary

Executive summary

• Revenue in Q2 2025 increased by 40% year-over-year, driven by strong testkit sales and recurring revenue, especially in Water Utility and Oil & Gas segments.

• Year-to-date (YTD) revenue reached DKK 4.1 million, up 36% compared to the same period last year, with growth attributed to both hardware and consumables.

Financial highlights

• Q2 2025 revenue rose 40% over Q2 2024, with recurring revenue showing double-digit growth, though below expectations due to delayed Pharma segment impact.

• YTD revenue of DKK 4.1 million, a 36% increase year-over-year, supported by delivery of 8 online robot samplers in Q1 and higher testkit sales in Q2.

Outlook and guidance

• 2025 revenue guidance revised downward to DKK 8–11 million from previous DKK 10–14 million.

• 2025 EBITDA now expected in the range of DKK -9 to -12 million, compared to earlier guidance of DKK -8 to -11 million.